Wegovy vs Zepbound Cost: What Drives GLP-1 Pricing

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The PlexusDx Education Hub breaks down GLP-1 pricing, weight-management protocols, and the genetics behind every metabolic decision. Browse all Peptides & GLP-1 education

This comparison is editorially independent. PlexusDx has no commercial relationship with the manufacturers of the products reviewed.

When people search for Wegovy versus Zepbound on cost, the real question is usually broader: why do GLP-1 medications carry the prices they do, and what actually changes the number at the pharmacy counter? This article, current as of April 2026, leads with pricing structure across the class, then places both drugs in the wider brand landscape and the genetics that no price tag reflects.

What actually drives GLP-1 pricing

The headline list price of a GLP-1 medication is only the starting line. What a patient ultimately pays is shaped by insurance coverage, the FDA indication written on the prescription, manufacturer savings-card eligibility, and whether a compounded alternative is accessible through a licensed compounding pathway. As of April 2026, list prices for the FDA-approved brands range roughly $815 to $1,620 per month at U.S. list price (manufacturer published pricing) — a spread that reflects molecule, brand, and indication rather than a single market rate.

The wider brand-and-indication map

Cost tracks closely with indication, so the full map matters. Ozempic (semaglutide) is approved for type 2 diabetes (2017); Wegovy (semaglutide 2.4 mg) for chronic weight management (2021); Rybelsus (oral semaglutide) for type 2 diabetes (2019); Mounjaro (tirzepatide) for type 2 diabetes (2022); Zepbound (tirzepatide) for chronic weight management (2023) and obstructive sleep apnea (2024, SURMOUNT-OSA); Trulicity (dulaglutide) for type 2 diabetes (2014); and Victoza (liraglutide) for type 2 diabetes (2010). Retatrutide, an investigational triple agonist, is not FDA-approved.

Cash pay, coverage, and compounded routes

Three access patterns dominate. Cash pay at list price is the most expensive route and least common. Insurance coverage can lower cost dramatically, but coverage frequently hinges on whether the prescription is for a covered diabetes indication versus a weight-management one. Compounded semaglutide or tirzepatide, dispensed through a licensed 503A compounding pathway, is a separate route with its own oversight and pricing. Which route applies changes the out-of-pocket figure more than the brand name does.

The trial evidence behind the class

Price aside, the class rests on a deep trial record: STEP (semaglutide for weight management), SUSTAIN and SELECT (semaglutide for diabetes and cardiovascular outcomes), SURMOUNT and SURPASS (tirzepatide for weight and diabetes), SURMOUNT-OSA (sleep apnea), LEAD and LEADER (liraglutide), and AWARD (dulaglutide). Head-to-head data exists for some pairings — SUSTAIN 7 (semaglutide 1 mg versus dulaglutide 1.5 mg) and SURPASS-2 (tirzepatide versus semaglutide 1 mg in type 2 diabetes). Populations and endpoints differ, so read per-trial.

Safety that cuts across price

Cost does not change the safety profile. Every FDA-approved GLP-1 receptor agonist and GIP/GLP-1 dual agonist carries the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and all are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal effects are most common; rare serious events include pancreatitis, gallbladder disease, and dehydration-related acute kidney injury.

The variable no price tag captures

No invoice reflects your inherited biology. Variants in FTO (fat-mass and obesity-associated), GLP1R (encoding the GLP-1 receptor every compound engages), MC4R (central to energy balance), and TCF7L2 (linked to glucose homeostasis and GLP-1 secretion) shape the metabolic terrain any compound works within. These pathway-level variants do not predict response to any one drug, but they map the biology you are paying to treat.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, GLP1R, MC4R, and TCF7L2 variants that shape your baseline biology. That is the test before you invest approach.

Related reading on PlexusDx: Wegovy for High Blood Pressure, Wegovy for Inflammation, Wegovy Qualifications, Wegovy vs GLP-1.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols and covers the mechanism, evidence, and genetic context that inform any decision to use them. PlexusDx does not sell, prescribe, or recommend any other GLP-1-category peptide beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

Why are GLP-1 medications so expensive?

List prices for FDA-approved brands run roughly $815 to $1,620 per month as of April 2026, reflecting molecule, brand, and indication. These are branded specialty medications, and the number at the counter shifts with coverage, savings cards, and whether the prescription is for a covered diabetes or weight-management indication.

Is Wegovy or Zepbound the cheaper option?

It depends far more on your coverage than on list price. Because insurers often treat diabetes and weight-management indications differently, the same person may find one far cheaper than the other. Compounded pathways add another route with separate pricing — compare your specific coverage before assuming either is cheaper.

Does insurance make GLP-1 drugs affordable?

Sometimes substantially, but coverage commonly hinges on indication. A plan may cover a diabetes prescription while restricting or excluding a weight-management one, even for the same molecule. Savings cards and manufacturer programs can help; confirm eligibility and coverage terms with your insurer and provider.

Can the genetic test lower my cost?

Not directly. The Precision Peptide Genetic Test is educational — it analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that describe your baseline biology. It informs the conversation with your provider before you invest in a protocol, but it does not predict drug response or change medication pricing.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.